Jeena Sikho Lifecare Limited, an Ayurveda healthcare provider, reported impressive Q1 FY26 results. Revenue increased 74% to ₹174.29 crore, EBITDA grew 220% to ₹78.79 crore, and net profit rose 218% to ₹51.31 crore. The company saw significant growth in patient volumes across IPD, OPD, video consultations, and day care services. Strategic developments include adding 391 new beds, migrating to NSE and BSE mainboard, and launching a new product. Management remains focused on scaling Panchkarma services and driving growth in Medicines & OTC sales for FY26.
14Aug 25
Jeena Sikho Lifecare to Host Q1 FY2025-26 Earnings Conference Call on August 18
Jeena Sikho Lifecare Limited (JSLL) will host a conference call on August 18, 2025, at 4:00 PM IST to discuss Q1 FY2025-26 operational and financial performance. Managing Director Manish Grover and CFO Nanak Chand will lead the call. Dial-in numbers for various countries are provided. JSLL recently reported Q1 revenue of Rs. 17,428.59 lakhs and profit after tax of Rs. 5,131.14 lakhs. The company, which migrated to the Main Board of BSE/NSE on August 11, 2025, operates in Ayurvedic medicines and therapies.
13Aug 25
Jeena Sikho Lifecare Limited Publishes Ayurvedic Research Articles and Announces Investor Events
Jeena Sikho Lifecare Limited has published six research articles on Ayurvedic treatments for various health conditions. The company has scheduled an investor conference call on August 18, 2025, to discuss Q1 FY 2025-26 financial performance. Additionally, Managing Director Manish Grover will attend Antique's Flagship Investor Conference on August 20, 2025, in Mumbai.
26Jun 25
Jeena Sikho Lifecare Secures Approval for 'Shuddhi Dr. Madhumeh' Diabetes Tablet Clinical Trials
Jeena Sikho Lifecare has received approval to conduct clinical trials for its diabetes tablet, 'Shuddhi Dr. Madhumeh'. This marks a significant step in the company's efforts to develop innovative diabetes treatment solutions. The clinical trials will evaluate the safety and efficacy of the tablet, which is designed specifically for diabetic patients. This development could potentially impact the diabetes care landscape, offering new treatment options for millions affected by the condition worldwide.